Light-Controlled Molecular Switch Wakes Dormant Lung Cancer Cells to Restore Treatment Vulnerability
Key Insights
ETH Zurich (search) researchers developed a light-controlled molecular switch that degrades glucocorticoid receptors, waking dormant lung cancer (search) cells from their protective sleep-like state.
The system harnesses the body's natural protein recycling machinery to tag receptors for destruction, with light used to deactivate the switch in healthy surrounding tissue.
In lab cultures of lung cancer (search) cells, the treatment rapidly broke down glucocorticoid receptors and gene activity analysis confirmed cells emerged from dormancy.
A team of researchers at ETH Zurich (search) has engineered a light-controlled molecular switch capable of rousing lung cancer (search) cells from a protective dormant state, potentially restoring their sensitivity to therapies that otherwise prove ineffective. The approach, which exploits the body's own protein recycling system, offers a path toward highly localized cancer treatment with significantly reduced side effects.
Tumor cells can enter a sleep-like state that allows them to evade the destructive effects of cancer drugs. In certain forms of lung cancer (search), this dormancy is triggered by stress hormones in the body. Inside cancer cells, glucocorticoid receptors detect these hormones, and the cells respond by slowing cell division dramatically—rendering many treatments far less effective.
The Challenge of Systemic Receptor Blockade
A major obstacle to targeting glucocorticoid receptors is their ubiquity. Every cell in the body carries these receptors, which perform essential functions including reducing inflammation and supporting normal immune system activity. Eliminating all glucocorticoid receptors throughout the body would cause disastrous side effects, creating an urgent need for a method that selectively destroys these receptors only in tumor cells.
A Three-Component Molecular Switch
The ETH Zurich (search) team, led by Katharina Gapp, Professor of Epigenetics and Neuroendocrinology, designed a system that triggers the destruction of glucocorticoid receptors inside tumor cells while using light to selectively neutralize the process in nearby healthy tissue.
"This system is based on existing medical technology and therefore offers a realistic prospect of localized therapies," said Robin Scheuplein, joint first author of the study and a doctoral student in Gapp's research group.
The molecular switch consists of three components: a sub-unit that binds to the glucocorticoid receptor (search), a flexible connecting piece, and another sub-unit that binds to the enzyme responsible for attaching a molecular "rubbish label" that marks proteins for disposal. Under normal lighting conditions, the connector remains extended, positioning the enzyme at the correct distance from the receptor to tag it for breakdown. When exposed to light of a specific wavelength, the connector bends, preventing proper alignment and halting the tagging process.
The connecting pieces were produced by the team led by Erick Carreira, Professor of Organic Synthesis at ETH Zurich (search). Testing confirmed that two of these connectors exhibited exactly the desired characteristics, allowing light to reliably flip the switch between a receptor-degrading state and an inactive one.
Waking Dormant Cells in the Lab
In laboratory cultures of lung cancer (search) cells, the researchers demonstrated the expected biological effect: the active substance led to rapid breakdown of the tumor cells' glucocorticoid receptors. Analysis of genetic activity further showed that the cells were woken from their dormant state as a result.
"Of course, this will now need to be verified in living organisms as well," Scheuplein noted.
The envisioned clinical application involves injecting the switch directly into a tumor and then using light to deactivate any molecules that migrate into surrounding healthy tissue. "Activity can therefore be strictly limited to the tumor core, preserving the surrounding tissue and causing significantly fewer side effects. The effect is reversible and can be controlled precisely," Scheuplein explained.
Overcoming Depth Limitations and Expanding Applications
Because light penetrates only a few millimeters into tissue, the light source must be positioned close to the tumor boundaries. For lung cancer (search), this could be achieved using an endoscope. For deeper-seated tumors, the research teams aim to develop switches that respond to longer wavelengths, such as near-infrared, which penetrate deeper and more gently into tissue.
The platform is inherently modular. "We've developed a modular system that we can also use to switch off other receptors," Scheuplein said. Potential clinical targets include the estrogen receptor (search) in hormone-dependent breast cancer (search) and the androgen receptor (search) in advanced prostate cancer (search). The system is already ready for use as a research tool to clarify complex signaling pathways in cancer biology.